🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants

Recruitingn/aAges 18 Years - anyFemaleIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT06794190 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The present study is therefore aimed at investigating the prevalence of hepatic alterations (laboratory and imaging) in adult patients with TS and generating hypothesissto the possible etiopathogenetic factors most involved, as well as evaluating the correlation between biochemical and structural abnormalities. Thus, the study could provide relevant etiopathogenetic and prognostic results on the development of hepatopathy in TS patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of Turner syndrome made by karyotype analysis on peripheral blood. * Age 18 years or older * Written informed consent obtained Exclusion Criteria: * TS patients on therapy with drugs responsible for significant liver enzyme alterations (liver function alteration, LFA).
💊

What it tests

  • Not listed
📍

Where

1 site
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy